Keros Therapeutics (NASDAQ:KROS) Shares Gap Down – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $17.55, but opened at $16.70. Keros Therapeutics shares last traded at $16.47, with a volume of 315,171 shares changing hands.

Analyst Upgrades and Downgrades

KROS has been the topic of several recent research reports. Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Oppenheimer restated an “outperform” rating and set a $27.00 price target (up previously from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.22.

Keros Therapeutics Price Performance

The company’s fifty day simple moving average is $15.78 and its 200-day simple moving average is $14.80. The firm has a market capitalization of $529.87 million, a PE ratio of 11.29, a P/E/G ratio of 0.37 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. During the same quarter in the prior year, the firm earned ($1.41) EPS. The company’s revenue for the quarter was up 3585.6% on a year-over-year basis. Analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The SEC filing for this sale provides additional information. Insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KROS. CWM LLC grew its stake in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Keros Therapeutics in the third quarter valued at approximately $47,000. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics in the third quarter valued at approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Keros Therapeutics by 29.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after purchasing an additional 1,892 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.